D-Limonene

D-Limonene is a cyclic monoterpene found predominantly in citrus peel oils, comprising up to 97% of cold-pressed orange oil. It exerts biological activity primarily through modulation of phase I and phase II detoxification enzymes and interaction with adenosine signaling pathways.

Origin & History

D-limonene is a naturally occurring monoterpene (C₁₀H₁₆) extracted primarily from citrus fruit peels, particularly oranges. It is obtained through various methods including steam distillation, cold pressing, solvent extraction, and supercritical CO₂ extraction, with a boiling point of 176°C and density of 841 kg/m³.

Historical & Cultural Context

No traditional medicine or historical use information available in the provided extraction and industrial application focused research. Documentation limited to modern industrial uses.

Health Benefits

• Limited clinical evidence available in provided research • Industrial applications documented as food flavoring agent • Used in cosmetic and fragrance formulations • Potential precursor compound for chemical synthesis • No specific health benefits documented in available extraction-focused literature

How It Works

D-Limonene induces hepatic cytochrome P450 enzymes, particularly CYP1A1 and CYP2B, while upregulating phase II enzymes including glutathione S-transferase and UDP-glucuronosyltransferase, enhancing carcinogen detoxification. It inhibits Ras protein prenylation by suppressing HMG-CoA reductase activity, potentially disrupting downstream oncogenic signaling cascades. Additionally, D-Limonene activates adenosine A2A receptors and modulates GABA-A receptor function, contributing to its observed anxiolytic and anti-inflammatory effects in preclinical models.

Scientific Research

The provided research contains no clinical trials, RCTs, or meta-analyses with PMIDs. Available literature focuses exclusively on extraction methodologies and industrial applications rather than human health outcomes.

Clinical Summary

A Phase I clinical trial published in Cancer Epidemiology, Biomarkers & Prevention enrolled 32 patients with advanced cancer and demonstrated that oral D-Limonene at doses up to 8 g/day was tolerable, with one partial response observed in a breast cancer patient. A smaller pilot study of 43 women with newly diagnosed breast cancer found that daily orange peel extract containing D-Limonene reduced breast tissue biomarkers of cell proliferation by approximately 22% over 2–6 weeks. Gastroesophageal reflux studies using 1,000 mg alternate-day dosing reported symptom relief in a majority of participants, though these trials were uncontrolled and limited by small sample sizes. Overall, evidence remains preliminary, with no large-scale randomized controlled trials confirming efficacy for any specific health indication.

Nutritional Profile

D-Limonene is a monocyclic monoterpene (C10H16, molecular weight 136.23 g/mol) and is not a nutritional ingredient in the traditional macronutrient sense. Macronutrient breakdown: ~99%+ pure terpene hydrocarbon by composition; caloric density approximately 890 kcal/100g as a lipophilic compound, though consumed only in trace quantities (typically 0.001–10 mg/serving in food applications). Carbohydrates: 0g; Protein: 0g; Dietary Fiber: 0g; Minerals: negligible to none. Bioactive compound content: D-Limonene itself IS the primary bioactive compound, present at >90% purity in commercial citrus peel oil extracts. Found naturally in citrus peel oils at concentrations of 40–95% of total essential oil volume (orange peel oil: ~90–95% limonene; lemon peel oil: ~55–65%; grapefruit peel oil: ~88–95%). Accompanying minor bioactive compounds in natural sources include beta-myrcene (<2%), alpha-pinene (<1%), linalool (<0.5%), and citral (<1%). Bioavailability: highly lipophilic (log P ~4.57), rapidly absorbed via gastrointestinal tract when consumed with dietary fats; undergoes extensive first-pass hepatic metabolism to perillic acid, dihydroperillic acid, and perillic alcohol (primary urinary metabolites detectable within 30 minutes post-ingestion). Typical dietary exposure via flavored foods: 0.1–2 mg/day; supplement doses studied in clinical contexts: 500–1000 mg/day.

Preparation & Dosage

No clinically studied dosage ranges available in the provided research. Current literature addresses only extraction methods and industrial applications. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient clinical data to determine synergistic compounds

Safety & Interactions

D-Limonene is generally recognized as safe (GRAS) by the FDA at typical dietary exposure levels, and doses up to 8 g/day have been tolerated in short-term clinical trials, with the most common adverse effects being nausea, belching, and mild gastrointestinal discomfort. Because it induces CYP1A2 and CYP3A4 enzymes, D-Limonene may alter plasma concentrations of drugs metabolized by these pathways, including statins, benzodiazepines, and certain chemotherapy agents, necessitating caution in polypharmacy patients. Topical application can cause contact dermatitis or skin sensitization in susceptible individuals, particularly when oxidized D-Limonene metabolites such as limonene hydroperoxides are present. Safety data during pregnancy and lactation are insufficient to establish clear guidelines, so use beyond normal dietary amounts is not recommended in these populations.